NANJING, China, SHANGHAI and SINGAPORE, Aug. 13, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio") today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based immune cell engineering and cell therapy company.

This acquisition marks a key milestone in IASO Bio's globalization strategy. By integrating MediSix's differentiated T-cell engineering platform, R&D pipeline, and international talent team with IASO Bio's cell therapy, manufacturing and commercialization capabilities, IASO Bio will further strengthen its global R&D and operational systems and accelerate the international development and commercialization of innovative cell therapy products.

Founded in 2016 and headquartered in Singapore, MediSix Therapeutics was established based on the research work of Professor Dario Campana, an internationally renowned translational immunology expert of the Yong Loo Lin School of Medicine at the National University of Singapore and a pioneer of 4-1BB (CD137) co-stimulatory domain CAR technology. MediSix has been backed by international institutional investors including ClavystBio, Lightstone Ventures, Osage University Partners, and EDBI (investment platform of Economic Development Board of Singapore and Enterprise Singapore, under SG Growth Capital). With their support, MediSix has built a robust R&D infrastructure, talent network, and international collaboration system.

MediSix's core technology focuses on addressing key challenges in cell therapy for T-cell malignancies. Its proprietary PEBL (Protein Expression Blocker) platform can specifically block the expression of target proteins on cell surfaces, effectively reducing fratricide among CAR-T cells. This enables targeting of antigens shared between T cells and target cells, and by combining ex vivo and in vivo CAR-T approaches, has established exclusive technological barriers and advantages for treating hematologic malignancies, solid tumors, and other diseases.

MediSix has also developed a differentiated pipeline addressing multiple unmet clinical needs. Its lead programme, IASO107 (formerly PCART7), is undergoing clinical evaluation in collaboration with leading international recognized research hospitals, and early clinical experience has shown promising efficacy and safety signals.

Ms. Zhang Jinhua, Founder, Chairwoman and CEO of IASO Bio, stated: "This acquisition represents a major milestone in the company's globalization strategy. MediSix has an outstanding scientific team and a differentiated PEBL technology platform with unique advantages in T-cell malignancies and AML that strongly complement IASO Bio's existing pipeline. Following this acquisition, MediSix will continue to develop follow-on products leveraging its unique platform, while harnessing IASO Bio's cost advantages and execution efficiency in CMC and clinical development to accelerate its international development. Furthermore, the addition of MediSix's international team will significantly enhance the company's R&D capabilities, talent attraction, and global collaboration network in the cell therapy field. We believe that through deep synergies between the two teams, we will accelerate the development of innovative cell therapy products and bring breakthrough therapies to more patients worldwide."

Mike Carusi, Chairman of MediSix and Managing Partner of Lightstone Ventures, stated: "On behalf of MediSix and its investors, we are delighted to see MediSix join forces with IASO Bio. IASO Bio brings a proven full-process platform, deep CMC and clinical development expertise, and a demonstrated track record of advancing a CAR-T therapy from the laboratory to commercial approval — a strong complement to MediSix's PEBL platform and T-cell engineering strengths. On this foundation, we expect MediSix's clinical programmes to accelerate, with the combined capabilities of both companies offering significant value over the long term."

KHOO Shih, CEO of ClavystBio, stated: "We see the strengths of MediSix and IASO Bio as highly complementary, with strong cross-border synergies, and believe the combined company can bring innovative cell therapies to patients around the world faster and at a greater scale."

About IASO Bio

Founded in 2017, IASO Bio is one of the first few commercial stage biopharmaceutical companies in China's Advanced Therapy Medicinal Products (ATMP) field to bring breakthrough innovations to the global market. We focus on cell therapies and biologics targeting hematologic malignancies and autoimmune diseases, with a full-process platform covering drug discovery, development, manufacturing, and commercialization.

The company has established a robust and highly synergistic R&D pipeline comprising 10 marketed and investigational products, including its core product, Equecabtagene Autoleucel Injection. This CAR-T cell therapy has been approved for marketing in China for the treatment of relapsed/refractory multiple myeloma (r/r MM) in patients who have progressed after at least three prior lines of therapy. The company is also developing this product for earlier lines of r/r MM treatment, as well as for autoimmune diseases including myasthenia gravis (MG), multiple sclerosis (MS), and systemic lupus erythematosus (SLE)/lupus nephritis (LN). In addition, the company has 9 other investigational products, including 3 autologous CAR-T cell therapies, 5 in vivo CAR-T cell therapies, and 1 antibody drug candidate.

IASO Bio has also established strategic collaborations with leading global biotechnology and pharmaceutical companies such as Innovent Biologics, Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, as well as top academic institutions and hospitals, continuously strengthening its product development capabilities.

With an experienced management team in the ATMP field, exceptional execution capabilities, a highly synergistic innovative R&D pipeline, and advanced manufacturing and CMC capabilities, IASO Bio remains dedicated to bringing transformative cell therapies to more patients worldwide.

About MediSix Therapeutics

MediSix Therapeutics is an immune cell engineering and cell therapy company headquartered in Singapore, founded in 2016 by CAR-T pioneer Professor Dario Campana. The company focuses on developing innovative T-cell therapies for T-cell malignancies, other tumors, and autoimmune diseases, with a proprietary PEBL (Protein Expression Blocker) technology platform and end-to-end R&D capabilities spanning from scientific discovery to clinical translation.